Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955525

Authors

Ammad Ahmad Farooqi

Gulnara Kapanova

Sundetgali Kalmakhanov

Gulnur Tanbayeva

Kairat S Zhakipbekov

Venera S Rakhmetova

Marat K Syzdykbayev

Affiliations

Soon will be listed here.

Abstract

Landmark discoveries in molecular oncology have provided a wide-angle overview of the heterogenous and therapeutically challenging nature of cancer. The power of modern 'omics' technologies has enabled researchers to deeply and comprehensively characterize molecular mechanisms underlying cellular functions. Interestingly, high-throughput technologies have opened new horizons for the design and scientific fool-proof evaluation of the pharmacological properties of targeted chemical compounds to tactfully control the activities of the oncogenic protein networks. Groundbreaking discoveries have galvanized the expansion of the repertoire of available pharmacopoeia to therapeutically target a myriad of deregulated oncogenic pathways. Natural product research has undergone substantial broadening, and many of the drugs which constitute the backbone of modern pharmaceuticals have been derived from the natural cornucopia. Baicalein has gradually gained attention because of its unique ability to target different oncogenic signal transduction cascades in various cancers. We have partitioned this review into different sub-sections to provide a broader snapshot of the oncogenic pathways regulated by baicalein. In this review, we summarize baicalein-mediated targeting of WNT/β-catenin, AKT/mTOR, JAK/STAT, MAPK, and NOTCH pathways. We also critically analyze how baicalein regulates non-coding RNAs (microRNAs and long non-coding RNAs) in different cancers. Finally, we conceptually interpret baicalein-mediated inhibition of primary and secondary growths in xenografted mice.

Citing Articles

Targeting Wnt/β-Catenin Pathway by Flavonoids: Implication for Cancer Therapeutics.

Pandey P, Khan F, Seifeldin S, Alshaghdali K, Siddiqui S, Abdelwadoud M Nutrients. 2023; 15(9).

PMID: 37432240 PMC: 10181252. DOI: 10.3390/nu15092088.

Comparative investigation on variations of nutritional components in whole seeds and seed coats of Korean black soybeans for different crop years and screening of their antioxidant and anti-aging properties.

Lee J, Seo E, Lee Y Food Chem X. 2023; 17:100572.

PMID: 36845484 PMC: 9944501. DOI: 10.1016/j.fochx.2023.100572.

References

Park C, Han S, Nam-Goong I, Kim Y, Kim E . Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. Endocrinol Metab (Seoul). 2018; 33(1):121-132. PMC: 5874188. DOI: 10.3803/EnM.2018.33.1.121. View

Wu R, Murali R, Kabe Y, French S, Chiang Y, Liu S . Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology. 2018; 68(5):1726-1740. PMC: 6204108. DOI: 10.1002/hep.30071. View

Chen X, Zhou Y, Wang S, Wang W . Mechanism of Baicalein in Brain Injury After Intracerebral Hemorrhage by Inhibiting the ROS/NLRP3 Inflammasome Pathway. Inflammation. 2021; 45(2):590-602. DOI: 10.1007/s10753-021-01569-x. View

Li J, Ma J, Wang K, Mi C, Wang Z, Piao L . Baicalein inhibits TNF-α-induced NF-κB activation and expression of NF-κB-regulated target gene products. Oncol Rep. 2016; 36(5):2771-2776. DOI: 10.3892/or.2016.5108. View

Zhao X, Qu J, Liu X, Wang J, Ma X, Zhao X . Baicalein suppress EMT of breast cancer by mediating tumor-associated macrophages polarization. Am J Cancer Res. 2018; 8(8):1528-1540. PMC: 6129485. View

Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X . Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem. 2015; 406(1-2):111-9. PMC: 4502300. DOI: 10.1007/s11010-015-2429-8. View

Yan H, Xin S, Wang H, Ma J, Zhang H, Wei H . Baicalein inhibits MMP-2 expression in human ovarian cancer cells by suppressing the p38 MAPK-dependent NF-κB signaling pathway. Anticancer Drugs. 2015; 26(6):649-56. DOI: 10.1097/CAD.0000000000000230. View

Luo J, Kong J, Dong B, Huang H, Wang K, Wu L . Baicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P. aeruginosa-infected macrophages by downregulating the MAPK and NFκB signal-transduction pathways. Drug Des Devel Ther. 2016; 10:183-203. PMC: 4708194. DOI: 10.2147/DDDT.S97221. View

Recio C, Guerra B, Guerra-Rodriguez M, Aranda-Tavio H, Martin-Rodriguez P, de Mirecki-Garrido M . Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology. Oncogene. 2019; 38(24):4657-4668. DOI: 10.1038/s41388-019-0752-3. View

10.

Chen Y, Zhang J, Zhang M, Song Y, Zhang Y, Fan S . Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clin Transl Med. 2021; 11(11):e577. PMC: 8567056. DOI: 10.1002/ctm2.577. View

11.

Bie B, Sun J, Guo Y, Li J, Jiang W, Yang J . Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma. Biomed Pharmacother. 2017; 93:1285-1291. DOI: 10.1016/j.biopha.2017.07.068. View

12.

Chen M, Zhong K, Tan J, Meng M, Liu C, Chen B . Baicalein is a novel TLR4-targeting therapeutics agent that inhibits TLR4/HIF-1α/VEGF signaling pathway in colorectal cancer. Clin Transl Med. 2021; 11(11):e564. PMC: 8567042. DOI: 10.1002/ctm2.564. View

13.

Salzman J, Gawad C, Wang P, Lacayo N, Brown P . Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012; 7(2):e30733. PMC: 3270023. DOI: 10.1371/journal.pone.0030733. View

14.

Tang J, Yan B, Tang Y, Zhou X, Ji Z, Xu F . Baicalein ameliorates oxidative stress and brain injury after intracerebral hemorrhage by activating the Nrf2/ARE pathway via miR-106a-5p/PHLPP2 axis. Int J Neurosci. 2022; 133(12):1380-1393. DOI: 10.1080/00207454.2022.2080676. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Yu M, Qi B, Xiaoxiang W, Xu J, Liu X . Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 2017; 90:677-685. DOI: 10.1016/j.biopha.2017.04.001. View

17.

Choi E, Cho E, Jeong J, Park C, Hong S, Hwang H . Baicalein Inhibits the Migration and Invasion of B16F10 Mouse Melanoma Cells through Inactivation of the PI3K/Akt Signaling Pathway. Biomol Ther (Seoul). 2016; 25(2):213-221. PMC: 5340547. DOI: 10.4062/biomolther.2016.094. View

18.

Song L, Chen X, Wang P, Gao S, Qu C, Liu L . Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Acta Biochim Biophys Sin (Shanghai). 2018; 50(6):586-596. DOI: 10.1093/abbs/gmy045. View

19.

Behrens J, Jerchow B, Wurtele M, Grimm J, Asbrand C, Wirtz R . Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998; 280(5363):596-9. DOI: 10.1126/science.280.5363.596. View

20.

Tian J, Li J, Bie B, Sun J, Mu Y, Shi M . MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling. Toxicol Appl Pharmacol. 2021; 420:115522. DOI: 10.1016/j.taap.2021.115522. View